04:58 PM EDT, 08/07/2024 (MT Newswires) -- Revolution Medicines ( RVMD ) reported a Q2 net loss late Wednesday of $0.81 per diluted share, compared with a loss of $0.92 per share a year earlier.

Analysts polled by Capital IQ expected a loss of $0.78.

The company did not report any revenue in the quarter.

For 2024, the clinical-stage oncology company said it continues to expect a net loss of $560 million to $600 million. It also projects current cash, cash equivalents and marketable securities can fund planned operations into 2027.